The single-blind, randomised phase II trial will include 300 volunteers. 240 participants will receive the ChAdOx1 nCoV-19 vaccine, while the remaining 60 will receive a control meningitis vaccine to act as a placebo.
"The government has stated that everyone living in the UK will be able to access the vaccine, however failure to provide the right documentation as well as fear of accessing healthcare services are preventing people from receiving the vaccine."
dditionally, the Oxford vaccine may be effective in reducing transmission of coronavirus. Based on swabs obtained from volunteers in the UK, there was a 67% reduction in positive tests among those who had been vaccinated.
I would argue that the vaccine rollout has been one of the few British successes to quietly emerge from the pandemic, primarily as the government has taken a step back and left it to non-partisan public bodies to head the process.
The European Medicines Agency has approved the Oxford/AstraZeneca COVID-19 vaccine for use in adults. The vaccine is the third to be given approval from the regulator.
Initial laboratory tests indicate that the Pfizer-BioNTech vaccine is effective against the B117 variant which emerged in Kent. However, there are concerns that variants which emerged in Brazil and South Africa may be resistant to the vaccines being rolled out worldwide.
Brendan Wren, professor of vaccinology at the London School of Hygiene and Tropical medicine, said modifying the vaccines would be relatively easy. It would involve making small changes to the genetic material they contain and would only take a matter of days to incorporate.
"Oxford-AstraZeneca has devised a vaccine in an unprecedented amount of time... However, with any and all science, it is important that we be critical of the claims being made, and question the scientific method used to arrive at such conclusions."
Oxford’s vaccine development team has received a £3.33 million gift from Wafic Saïd. The money will be used to fund the professorship in vaccinology,...
Clinical trials for the COVID-19 vaccine being developed by Oxford University are set to resume, after they were halted on September 6th following concerns...